• September 29, 2009KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
• July 27, 2009Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China
• April 3, 2009Change of Representative Director and President at KYORIN Pharmaceutical
• February 27, 2009Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO
• January 29, 2009Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008
• December 24, 2008Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
• October 1, 2008Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
• September 30, 2008Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan
• August 20, 2008Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
• April 22, 2008Execution of License Agreement on Flutiform, an Anti-asthmatic Treatment, in Japan
• April 18, 2008Launch of KIPRES Tablets 5mg
• March 3, 2008Pentasa Tablets 250 Received Approvals For Additional Pediatric Indication
• February 21, 2008Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
• January 30, 2008Execution of an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
• January 25, 2008KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis
• October 12, 2007Discontinuation of Cooperation on Baynas Marketing for Treatment of Allergic Rhinitis by Kyorin Pharmaceutical Co.,Ltd. and Bayer Yakuhin,Ltd.
• October 2, 2007Launch of "KIPRES" Oral Granules 4mg
• September 26, 2007Merger between Kyorin Phamaceutical Co.,Ltd. and Nisshin Kyorin Pharmaceutical Co.,Ltd.
• July 31, 2007Marketing Approval for "KIPRES" Oral Granules 4mg
• April 28, 2006Kyorin Licensee Announces Decision to Stop Commercialization of Tequin
• March 10, 2006On the Transition to a Holding - Company Structure
• March 10, 2006On Kyorin Corporate Branding and the establishment of a New Corporate Mark & Logotype
• March 7, 2006On the start of phase 1 for KRP-104, therapeutic agent for diabetes, in USA
• November 18, 2005Notice of Group Reorganization in association with Transition to Holding-Company Structure through Share Exchange
• November 9, 2005Favorable Ruling for Gatifloxacin Patent Dispute in Canada
• August 1, 2005EXECUTION OF MOU WITH LG LIFE SCIENCES FOR KRP-197
• June 13, 2005Dr.Program Co.,Ltd.Becomes a Wholly-Owned Subsidiary of Kyorin Pharmaceutical Co.,Ltd.
• May 12, 2005Kyorin to Announce MIC-'09 Mid-Term Business Plans
• March 31, 2005Kyorin Pharmaceutical to Acquire Toyo Pharmar Stock to Establish a Subsidiary
• December 1, 2004Kyorin Pharmaceutical Announces Signing of Acquisition Agreement of ActivX Biosciences
• October 25, 2004Conclusion of license agreement for IBUDILAST with MEDICINOVA
• September 7, 2004Launch of GATIFLO 0.3% Eye Drops,a Broad-spectrum,Antibacterial Ophthalmic Solution,in Japan
• August 19, 2004Kyorin Executes Patent License and Collaborative Research and Development Agreement with Merck & Co., Inc.
• March 24, 2004Kyorin Announces the Filing of a Lawsuit for Patent Infringment Aganist TEVA in the United States
• September 3, 2003Agreement on Sponsored Discovery Research With Partners International,Inc(DPI)
• August 25, 2003Construction of New Production System
• August 22, 2003Co-Promotion of Anti-Allergic Drug, "Allelock Tablets"
• July 30, 2003Partial Amendment of the Marketing Alliance Agreement for the Migraine Treatment MAXALT
• April 23, 2003Kyorin,Teijin Announce Intentions to Cease Planned Business Integration
• February 26, 2003Kyorin and Esai Form an Alliance on Marketing of "rizatriptan benzoate" (generic name), an agent for migraine

1 2 3